Table 7a. Fluvoxamine: Selected Clinical Trial Data
Last Updated: December 20, 2023
The clinical trials described in this table do not represent all the trials that the Panel reviewed while developing the recommendations for fluvoxamine. The studies summarized below are the randomized clinical trials that have had the greatest impact on the Panel’s recommendations.
Table 7a. Fluvoxamine: Selected Clinical Trial Data | |
|---|---|
References
- McCarthy MW, Naggie S, Boulware DR, et al. Effect of fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2023;329(4):296-305. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36633838.
- Stewart TG, Rebolledo PA, Mourad A, et al. Higher-dose fluvoxamine and time to sustained recovery in outpatients with COVID-19: the ACTIV-6 randomized clinical trial. JAMA. 2023;330(24):2354-2363. Available at: https://www.ncbi.nlm.nih.gov/pubmed/37976072.
- Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized trial of metformin, ivermectin, and fluvoxamine for COVID-19. N Engl J Med. 2022;387(7):599-610. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36070710.
- Reis G, Dos Santos Moreira-Silva EA, Medeiros Silva DC, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10(1):e42-e51. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34717820.
- Reis G, Mills E. Fluvoxamine for the treatment of COVID-19 - Author's reply. Lancet Glob Health. 2022;10(3):e333. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35180413.
- Reiersen AM, Mattar C, Bender Ignacio RA, et al. The STOP COVID 2 study: fluvoxamine vs placebo for outpatients with symptomatic COVID-19, a fully remote randomized controlled trial. Open Forum Infect Dis. 2023;10(8):ofad419. Available at: https://www.ncbi.nlm.nih.gov/pubmed/37622035.
- Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324(22):2292-2300. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33180097.
- Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, et al. Oral fluvoxamine with inhaled budesonide for treatment of early-onset COVID-19: a randomized platform trial. Ann Intern Med. 2023;176(5):667-675. Available at: https://www.ncbi.nlm.nih.gov/pubmed/37068273.